Abstracts tagged "DMARDs"

Abstract Number: 2587 • 2018 ACR/ARHP Annual Meeting
The Impact of Tumor Necrosis Factor Inhibitors on Diabetes Mellitus Among Patients with Inflammatory Arthritis
Santhi Mantravadi¹, Michael D. George² and Alexis Ogdie³, ¹Department of Clinical Pharmacology, Division of Rheumatology, Jefferson University School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Tumor necrosis factor (TNF) is a key inflammatory cytokine in the pathogenesis of psoriatic arthritis (PsA), RA, ankylosing spondylitis (AS), and diabetes mellitus (DM). …
Abstract Number: 561 • 2018 ACR/ARHP Annual Meeting
U-Act-Early Trial 3 Years Follow-up: Radiographic Joint Damage and Use of Bdmards over 5 Years in Early RA Patients Treated-to-Target with Strategies Initiating Tocilizumab, Methotrexate or Their Combination
Maxime MA Verhoeven¹, Maria JH de Hair², Paco MJ Welsing², Attila Pethö-Schramm³, Michelle EA Borm⁴, Xavier M Teitsma², Jacob van Laar², Floris PJG Lafeber², Johannes W. J. Bijlsma⁵ and Johannes W. G. Jacobs⁶, ¹Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ³F. Hoffmann-La Roche, Basel, Switzerland, ⁴Roche Nederland BV, Woerden, Netherlands, ⁵Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: The U-Act-Early trial was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission, with step-up…
Abstract Number: 1401 • 2018 ACR/ARHP Annual Meeting
Is There a Specific Effect of Jak-Inhibitors on Pain and Fatigue in Rheumatoid Arthritis?
Itsaso Odriozola¹, Claire-Sophie Coste¹, Thomas Barnetche^2,3, Christophe Richez^4,5, Bernard Bannwarth¹ and Thierry Schaeverbeke⁶, ¹Rheumatology, CHU de Bordeaux, Bordeaux, France, ²FHU ACRONIM, Pellegrin Hospital, Bordeaux University, Bordeaux, France, ³Rheumatology, Centre hospitalier universitaire de Bordeaux - Service de Rhumatologie, Bordeaux, France, ⁴UMR CNRS 5164 - Immunoconcept, Bordeaux, France, ⁵Department of Rheumatology, Bordeaux University Hospital, Bordeaux, France, ⁶Department of Rheumatology, Bordeaux University Hospital, BORDEAUX, France
Background/Purpose: Pain and fatigue are common symptoms for patients with rheumatoid arthritis (RA).JAK inhibitors (JAKi) already proved similar efficacy on disease activity as bDMARD (anti-TNF,…
Abstract Number: 2344 • 2018 ACR/ARHP Annual Meeting
Treatment Modes in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
Peter C. Taylor¹, Neil Betteridge², T Michelle Brown³, John Woolcott⁴, Alan J. Kivitz⁵, Cristiano A F Zerbini⁶, Diane Whalley⁷, Oyebimpe Olayinka-Amao³, Connie Chen⁸, Palle Dahl⁹, Dario Ponce de Leon¹⁰, David Gruben¹¹ and Lara Fallon¹², ¹University of Oxford, Oxford, United Kingdom, ²Neil Betteridge Associates, London, United Kingdom, ³RTI Health Solutions, Research Triangle Park, NC, ⁴Pfizer Inc, Collegeville, PA, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶Centro Paulista de Investigação Clinica, São Paulo, Brazil, ⁷RTI Health Solutions, Manchester, United Kingdom, ⁸Pfizer Inc, New York, NY, ⁹Pfizer Inc, Ballerup, Denmark, ¹⁰Pfizer Inc, Lima, Peru, ¹¹Pfizer Inc, Groton, CT, ¹²Pfizer Canada, Montreal, QC, Canada
Background/Purpose: Treatment recommendations in RA emphasize shared decision-making,1 but little is known about patient (pt) perspectives. Through qualitative research, we aim to understand pt preferences…
Abstract Number: 2609 • 2018 ACR/ARHP Annual Meeting
Survival of Disease-Modifying Drugs in Patients with Recent Diagnosis of Psoriatic Arthritis in Daily Clinical Practice
Dalifer Freites Núñez¹, Zulema Rosales Rosado^1,2, Judit Font Urgelles², Isabel Hernández-Rodríguez², Leticia Leon¹, Gloria Candelas Rodriguez², Luis Rodriguez-Rodriguez¹, Benjamín Fernández-Gutiérrez^1,2, Juan A Jover Jover² and Lydia A Alcazar¹, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disease that benefits from DMARDs, in this regard knowing more about these therapies is a great step…
Abstract Number: 587 • 2018 ACR/ARHP Annual Meeting
The Superiority of a Treat to Target Strategy over Conventional Treatment with Fixed Csdmard and Corticosteroids: A Multi-Centre Randomized Controlled Trial in RA Patients with Inadequate Response to Conventional Synthetic Dmards, and a New Therapy with Certolizumab Pegol
Ruediger Mueller¹, Michael Spaeth², Cord von Restorff³, Christoph Ackermann⁴ and Johannes von Kempis⁵, ¹Division of Rheumatology, Kantonsspital St Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, Spital Linth, Uznach, Switzerland, ³Private rheumatologic practice, Männedorf, Switzerland, ⁴Private rheumatologic practice, Triesen, Liechtenstein, ⁵Division of Rheumatology and Immunology, Kantonsspital St. Gallen, St. Gallen, Switzerland
The superiority of a treat to target strategy over conventional treatment with fixed csDMARD and corticosteroids: a multi-centre randomized controlled trial in RA patients with…
Abstract Number: 1436 • 2018 ACR/ARHP Annual Meeting
Pregnancy Outcomes in Partners of DMARD Exposed Men with Juvenile Idiopathic Arthritis – an Observational Study
Paula Drechsel¹, Jens Klotsche², Martina Niewerth², Gerd Horneff³ and Kirsten Minden⁴, ¹Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Program Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ³Asklepios Clinic Sankt Augustin, and University Hospital of Cologne, Cologne, Germany, ⁴Epidemiology unit, German Rheumatism Research Center and Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Males account for about one third of all cases of juvenile idiopathic arthritis (JIA). During the course of the disease and often into adulthood,…
Abstract Number: 2366 • 2018 ACR/ARHP Annual Meeting
Facilitating Shared Decision Making in Psoriatic Arthritis: Factors Influencing Patient Preference for Treatment Mode of Administration
Daniel Aletaha¹, M. Elaine Husni², Joseph F. Merola³, Roberto Ranza⁴, Heidi Bertheussen⁵, Ralph Lippe⁶, Pamela Young⁷, Joseph C Cappelleri⁸, T Michelle Brown⁹, Claire Ervin⁹, Ming-Ann Hsu⁸ and Lara Fallon¹⁰, ¹Medical University of Vienna, Vienna, Austria, ²Cleveland Clinic, Orthopedic and Rheumatologic Institute, Cleveland, OH, ³Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Servicio de Reumatología, Universidade Federal de Uberlandia, Santa Mônica, Uberlândia, Brazil, ⁵Patient Representative, Oslo, Norway, ⁶Pfizer Pharma GmbH, Berlin, Germany, ⁷Pfizer Inc, Collegeville, PA, ⁸Pfizer Inc, Groton, CT, ⁹RTI Health Solutions, Research Triangle Park, NC, ¹⁰Pfizer Canada, Montreal, QC, Canada
Background/Purpose: Shared decision making is key to optimizing management of patients (pts) with psoriatic arthritis (PsA).1 Few studies have evaluated pt preferences for treatment administration…
Abstract Number: 2814 • 2018 ACR/ARHP Annual Meeting
Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
Fenglong Xie¹, Lang Chen¹, Emily Levitan², Paul M. Muntner² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Methotrexate (MTX) has been associated with reduced risk for cardiovascular disease (CVD) in several studies conducted among rheumatoid arthritis (RA) patients never exposed to…
Abstract Number: 603 • 2018 ACR/ARHP Annual Meeting
Rheumatologists Beliefs in the Effectiveness of Other Methotrexate-Based Treatment Approaches May Explain the Low Use of Triple Therapy: A Bayesian Belief Elicitation
Gyanendra Pokharel¹, Rob Deardon¹, Sindhu Johnson², George A. Tomlinson³ and Glen Hazlewood⁴, ¹Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada, ²Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ³Medicine, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Triple therapy (MTX, sulphasalazine (SSZ), hydroxychloroquine (HCQ)) has evidence to support its use from randomized trials (RCTs) but is not commonly used. The objective…
Abstract Number: 1480 • 2018 ACR/ARHP Annual Meeting
Prognosis of Pneumonia in Rheumatoid Arthritis Patient: An Analysis of Using a Nationwide Administrative Database
Eishi Uechi^1,2 and Kiyohide Fushimi², ¹Division of Rheumatology, Tomishiro Central Hospital, Okinawa, Japan, ²Department of Health Policy and Informatics, Tokyo Medical and Dental University Graduate School, Tokyo, Japan
Background/Purpose: Pneumonia is the leading cause of mortality in RA patients. No research has been conducted on the prognosis of pneumonia in RA patients. This…
Abstract Number: 2368 • 2018 ACR/ARHP Annual Meeting
Patient Preferences for Disease Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review
Caylib Durand¹, Maysoon Eldoma¹, Deborah A. Marshall² and Glen Hazlewood^1,3, ¹Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Community Health Sciences, University of Calgary, Calgary, AB, Canada, ³Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Treatment choices in rheumatoid arthritis (RA) involve trade-offs in risks, benefits and other considerations such as dosing. Understanding patient preferences for these trade-offs is…
Abstract Number: 2822 • 2018 ACR/ARHP Annual Meeting
Should We Prefer Leflunomide to Methotrexate in Combination with Biologics? a Systematic Review and a Meta-Analysis
Guillaume Decarriere¹, Thomas Barnetche², Cédric Lukas³, Cécile Gaujoux-Viala⁴, Bernard Combe⁵, Jacques Morel⁶ and Claire I. Daien⁷, ¹Department of Rheumatology, CHU Lapeyronie, Montpellier, France, ²Rheumatology Department, FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³Rheumatology, CHU Lapeyronie and EA2415, Montpellier University, University of Montpellier, France, ⁴Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, ⁵Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁶Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁷Department of rheumatology, Lapeyronie Hospital and Montpellier University, Montpellier, France
Background/Purpose: In rheumatoid arthritis (RA), biologics are more efficient in combination with methotrexate (MTX) than in monotherapy. When MTX cannot be used, others csDMARD can…
Abstract Number: 604 • 2018 ACR/ARHP Annual Meeting
Combining Observational and Randomized Controlled Trial Data Evidence to Jointly Estimate Remission and Response for Biologic and Non-Biologic Therapies in Rheumatoid Arthritis: A Bivariate Network Meta-Analysis
Gyanendra Pokharel¹, Rob Deardon¹, Cheryl Barnabe², Vivian P. Bykerk³, Susan J. Bartlett⁴, Louis Bessette⁵, Gilles Boire⁶, Carol Hitchon⁷, Edward C. Keystone⁸, Janet E. Pope⁹, Diane Tin¹⁰, Carter Thorne¹¹ and Glen Hazlewood¹², ¹Department of Mathematics and Statistics, University of Calgary, Calgary, AB, Canada, ²Medicine, University of Calgary, Calgary, AB, Canada, ³Hospital for Special Surgery, New York, NY, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁶Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁰The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹University of Toronto, Newmarket, ON, Canada, ¹²Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Remission is the goal of rheumatoid arthritis (RA) treatment, but ACR responses are more commonly measured in clinical trials. As such, data on remission…
Abstract Number: 1519 • 2018 ACR/ARHP Annual Meeting
Patient Characteristics Associated with Discontinuation of Tofacitinib for the Treatment of Rheumatoid Arthritis in Open-Label, Long-Term Extension Studies up to 9.5 Years
Jeffrey R. Curtis¹, Jürgen Wollenhaupt², Katerina Chatzidionysiou³, Sander W. Tas⁴, Lisy Wang⁵, Harry Shi⁶, María Montoro⁷, Petra Neregård⁸, Palle Dahl⁹ and Vassilis Tsekouras¹⁰, ¹University of Alabama at Birmingham, Birmingham, AL, ²Schön Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ³Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Amsterdam Rheumatology and Immunology Center, Academic Medical Center, Amsterdam, Netherlands, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Pfizer Inc, Madrid, Spain, ⁸Pfizer Inc, Stochholm, Sweden, ⁹Pfizer Inc, Ballerup, Denmark, ¹⁰Pfizer Inc, Athens, Greece
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. We explored characteristics of patients (pts) who discontinued (d/c) open-label, long-term extension…

« Previous Page
1
…
4
5
6
7
8
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.